The global neutropenia treatment market size reached US$ 15.3 Billion in 2023. Looking forward, the market is projected to reach US$ 23.8 Billion by 2032, exhibiting a growth rate (CAGR) of 5.03% during 2023-2032. The increasing adoption of cloud platforms, escalating sales of smartphones and extensive research and development (R&D) activities represent some of the key factors driving the market.
Neutropenia is a disease characterized by an abnormally low count of white blood cells (WBCs) that help the body fight infections. It is caused by various situations or diseases, including infections, chemotherapy, congenital bone marrow abnormalities, autoimmune disorders, and some medications (drug-induced neutropenia). Neutrophils are made in the bone marrow, which is the spongy tissue found in larger bones, such as the vertebrae, ribs, and pelvis. Neutropenia treatment includes antibiotics, antifungals, and antiviral medications that help fight against infection by destroying harmful fungi, yeast, and bacteria that attack the body. These medications assist in reducing the likelihood of infections and stimulate the bone marrow to produce more white blood cells.
In addition to this, manufacturers are focusing on the introduction of cost-effective medicines for neutropenia treatment, which is facilitating the market growth. Additionally, the utilization of novel drug delivery methods that helps in improving patient convenience, which leads to improved patient adherence, is positively influencing the market growth. Besides this, the increase in febrile neutropenia medications and the implementation of new legislation to promote and manufacture biosimilars are creating a positive outlook for the market.
The market is also driven by the easy availability of medications through online retail portals, such as registered websites, which provides convenience of ordering and procurement of medications at affordable price-points. Other factors, including extensive research and development (R&D) activities, the introduction of innovative and effective drugs, rising incidences of cancer, easy access to healthcare facilities owing to improved infrastructure, increasing expenditure capacities of consumers and the implementation of various government initiatives for promoting public health, are anticipated to drive the market growth.
2. What is the expected growth rate of the global neutropenia treatment market during 2024-2032?
3. What are the key factors driving the global neutropenia treatment market?
4. What has been the impact of COVID-19 on the global neutropenia treatment market?
5. What is the breakup of the global neutropenia treatment market based on the treatment?
6. What is the breakup of the global neutropenia treatment market based on the distribution channel?
7. What are the key regions in the global neutropenia treatment market?
8. Who are the key players/companies in the global neutropenia treatment market?
Neutropenia is a disease characterized by an abnormally low count of white blood cells (WBCs) that help the body fight infections. It is caused by various situations or diseases, including infections, chemotherapy, congenital bone marrow abnormalities, autoimmune disorders, and some medications (drug-induced neutropenia). Neutrophils are made in the bone marrow, which is the spongy tissue found in larger bones, such as the vertebrae, ribs, and pelvis. Neutropenia treatment includes antibiotics, antifungals, and antiviral medications that help fight against infection by destroying harmful fungi, yeast, and bacteria that attack the body. These medications assist in reducing the likelihood of infections and stimulate the bone marrow to produce more white blood cells.
Neutropenia Treatment Market Trends
The rising awareness of neutropenia and chemotherapy-related side effects is one of the key factors driving the market growth. In line with this, the increasing demand for oral drugs that are available in capsule and tablet form and consist of convenient routes of administration is favoring the market growth. Moreover, key players are actively engaged in disseminating relevant information and knowledge regarding preventive measures, early diagnosis, and effective treatment of neutropenia, which, in turn, is propelling the market growth. Furthermore, the increasing awareness among the masses regarding the available treatment alternatives is acting as another growth-inducing factor.In addition to this, manufacturers are focusing on the introduction of cost-effective medicines for neutropenia treatment, which is facilitating the market growth. Additionally, the utilization of novel drug delivery methods that helps in improving patient convenience, which leads to improved patient adherence, is positively influencing the market growth. Besides this, the increase in febrile neutropenia medications and the implementation of new legislation to promote and manufacture biosimilars are creating a positive outlook for the market.
The market is also driven by the easy availability of medications through online retail portals, such as registered websites, which provides convenience of ordering and procurement of medications at affordable price-points. Other factors, including extensive research and development (R&D) activities, the introduction of innovative and effective drugs, rising incidences of cancer, easy access to healthcare facilities owing to improved infrastructure, increasing expenditure capacities of consumers and the implementation of various government initiatives for promoting public health, are anticipated to drive the market growth.
Key Market Segmentation
This report provides an analysis of the key trends in each segment of the global neutropenia treatment market, along with forecasts at the global, regional, and country level from 2024-2032. The report has categorized the market based on treatment and distribution channel.Treatment Insights:
- Colony-Stimulating Factors
- Antibiotics
- Antifungals
- Antivirals
Distribution channel Insights:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape
The report has also provided a comprehensive analysis of the competitive landscape in the global neutropenia treatment market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Amgen Inc., BeyondSpring Inc., Kyowa Hakko Kirin Co. Ltd. (Kirin Holdings Company Limited), Pfizer Inc., Sandoz Inc. (Novartis AG), Spectrum Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.Key Questions Answered in This Report
1. How big is the global neutropenia treatment market?2. What is the expected growth rate of the global neutropenia treatment market during 2024-2032?
3. What are the key factors driving the global neutropenia treatment market?
4. What has been the impact of COVID-19 on the global neutropenia treatment market?
5. What is the breakup of the global neutropenia treatment market based on the treatment?
6. What is the breakup of the global neutropenia treatment market based on the distribution channel?
7. What are the key regions in the global neutropenia treatment market?
8. Who are the key players/companies in the global neutropenia treatment market?
Table of Contents
1 Preface3 Executive Summary10 Value Chain Analysis12 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Neutropenia Treatment Market
6 Market Breakup by Treatment
7 Market Breakup by Distribution Channel
8 Market Breakup by Region
9 Drivers, Restraints, and Opportunities
11 Porters Five Forces Analysis
13 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Amgen Inc.
- BeyondSpring Inc.
- Kyowa Hakko Kirin Co. Ltd. (Kirin Holdings Company Limited)
- Pfizer Inc.
- Sandoz Inc. (Novartis AG)
- Spectrum Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 137 |
| Published | April 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 15.3 Billion |
| Forecasted Market Value ( USD | $ 23.8 Billion |
| Compound Annual Growth Rate | 5.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 8 |
